CA3040513C - Comprime oral de cannabinoide - Google Patents

Comprime oral de cannabinoide Download PDF

Info

Publication number
CA3040513C
CA3040513C CA3040513A CA3040513A CA3040513C CA 3040513 C CA3040513 C CA 3040513C CA 3040513 A CA3040513 A CA 3040513A CA 3040513 A CA3040513 A CA 3040513A CA 3040513 C CA3040513 C CA 3040513C
Authority
CA
Canada
Prior art keywords
particles
oral tablet
tablet according
oral
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3040513A
Other languages
English (en)
Other versions
CA3040513A1 (fr
Inventor
Heidi Ziegler Bruun
Dorthe Schackinger Boesen
Ane Eriksen
Helle Wittorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordiccan AS
Original Assignee
Nordiccan AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3040513A priority Critical patent/CA3040513C/fr
Application filed by Nordiccan AS filed Critical Nordiccan AS
Priority to PCT/DK2020/050102 priority patent/WO2020211915A1/fr
Priority to PL20726699.0T priority patent/PL3920890T3/pl
Priority to FIEP20726699.0T priority patent/FI3920890T3/fi
Priority to MX2021012712A priority patent/MX2021012712A/es
Priority to EP20727578.5A priority patent/EP3920891B1/fr
Priority to CN202080029324.1A priority patent/CN113710235B/zh
Priority to BR112021020523A priority patent/BR112021020523A2/pt
Priority to JP2021561780A priority patent/JP2022529037A/ja
Priority to EP23196168.1A priority patent/EP4268815A3/fr
Priority to DK20726699.0T priority patent/DK3920890T3/da
Priority to EP23204541.9A priority patent/EP4289423A3/fr
Priority to PCT/DK2020/050100 priority patent/WO2020211913A1/fr
Priority to AU2020258631A priority patent/AU2020258631B2/en
Priority to FIEP20727578.5T priority patent/FI3920891T3/fi
Priority to AU2020259627A priority patent/AU2020259627B2/en
Priority to DK20727578.5T priority patent/DK3920891T3/da
Priority to ES20726699T priority patent/ES2966539T3/es
Priority to CN202080029225.3A priority patent/CN113784704A/zh
Priority to EP20726699.0A priority patent/EP3920890B1/fr
Priority to PL20727578.5T priority patent/PL3920891T3/pl
Publication of CA3040513A1 publication Critical patent/CA3040513A1/fr
Application granted granted Critical
Publication of CA3040513C publication Critical patent/CA3040513C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un comprimé oral qui administre des cannabinoïdes aux muqueuses et dont la population comprend des particules et au moins un cannabinoïde. La population des particules comprend des particules de polyalcool directement compressibles (DC) ainsi que des particules de polyalcool non directement compressible (non DC) qui fournissent plusieurs zones non DC discrètes.
CA3040513A 2019-04-17 2019-04-17 Comprime oral de cannabinoide Active CA3040513C (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CA3040513A CA3040513C (fr) 2019-04-17 2019-04-17 Comprime oral de cannabinoide
FIEP20727578.5T FI3920891T3 (fi) 2019-04-17 2020-04-17 Nopeasti hajoavat kannabinoiditabletit
AU2020258631A AU2020258631B2 (en) 2019-04-17 2020-04-17 Fast disintegrating cannabinoid tablets
MX2021012712A MX2021012712A (es) 2019-04-17 2020-04-17 Tabletas de cannabinoides de desintegracion rapida.
PL20726699.0T PL3920890T3 (pl) 2019-04-17 2020-04-17 Doustna tabletka kannabinoidowa
CN202080029324.1A CN113710235B (zh) 2019-04-17 2020-04-17 经口大麻素片剂
BR112021020523A BR112021020523A2 (pt) 2019-04-17 2020-04-17 Comprimidos de canabinoide de desintegração rápida
AU2020259627A AU2020259627B2 (en) 2019-04-17 2020-04-17 An oral cannabinoid tablet
EP23196168.1A EP4268815A3 (fr) 2019-04-17 2020-04-17 Comprimés multimodulaires de cannabinoïdes
DK20726699.0T DK3920890T3 (da) 2019-04-17 2020-04-17 Oral cannabinoid-tablet
PCT/DK2020/050102 WO2020211915A1 (fr) 2019-04-17 2020-04-17 Comprimés cannabinoïdes à désintégration rapide
PCT/DK2020/050100 WO2020211913A1 (fr) 2019-04-17 2020-04-17 Comprimé cannabinoïde oral
FIEP20726699.0T FI3920890T3 (fi) 2019-04-17 2020-04-17 Oraalinen kannabinoiditabletti
EP20727578.5A EP3920891B1 (fr) 2019-04-17 2020-04-17 Comprimés de cannabinoïdes à désintégration rapide
JP2021561780A JP2022529037A (ja) 2019-04-17 2020-04-17 速崩壊カンナビノイド錠剤
DK20727578.5T DK3920891T3 (da) 2019-04-17 2020-04-17 Hurtig desintegrerende cannabinoid-tabletter
ES20726699T ES2966539T3 (es) 2019-04-17 2020-04-17 Comprimido oral de cannabinoides
CN202080029225.3A CN113784704A (zh) 2019-04-17 2020-04-17 快速崩解大麻素片剂
EP20726699.0A EP3920890B1 (fr) 2019-04-17 2020-04-17 Comprimé oral de cannabinoïdes
PL20727578.5T PL3920891T3 (pl) 2019-04-17 2020-04-17 Szybko rozpadające się tabletki kannabinoidowe
EP23204541.9A EP4289423A3 (fr) 2019-04-17 2020-04-17 Comprimé oral de cannabinoïdes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3040513A CA3040513C (fr) 2019-04-17 2019-04-17 Comprime oral de cannabinoide

Publications (2)

Publication Number Publication Date
CA3040513A1 CA3040513A1 (fr) 2020-10-17
CA3040513C true CA3040513C (fr) 2021-08-24

Family

ID=72896209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3040513A Active CA3040513C (fr) 2019-04-17 2019-04-17 Comprime oral de cannabinoide

Country Status (1)

Country Link
CA (1) CA3040513C (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160750A1 (fr) 2019-12-09 2021-06-17 Anthony Richard Gerardi Produit a usage oral comprenant un cannabinoide
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2024008261A1 (fr) * 2022-07-05 2024-01-11 Fertin Pharma A/S Prémélange de cannabinoïdes et de lipides
CN115644438A (zh) * 2022-11-04 2023-01-31 中华全国供销合作总社济南果品研究所 一种含西洋参、无花果的提神益智含片及其制备方法

Also Published As

Publication number Publication date
CA3040513A1 (fr) 2020-10-17

Similar Documents

Publication Publication Date Title
US11903919B2 (en) Oral cannabinoid tablet
CA3040513C (fr) Comprime oral de cannabinoide
AU2020259627B2 (en) An oral cannabinoid tablet
US20240065973A1 (en) Tableted Cannabinoid Chewing Gum With Tableted Modules
US20220323349A1 (en) Cannabinoid chewing gum with high intensity sweeteners
US10933017B2 (en) Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US20200237658A1 (en) Cannabinoid chewing gum with improved release of cannabinoids
US11471405B2 (en) Tableted chewing gum with enhanced delivery of cannabinoids
AU2020258631B2 (en) Fast disintegrating cannabinoid tablets
US11633351B2 (en) Fast disintegrating cannabinoid tablets
US11253473B2 (en) Method of producing tableted cannabinoid chewing gum
EP3876744B1 (fr) Gomme à mâcher à base de cannabinoïdes en comprimés à structure stratifiée
US11154496B2 (en) Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
CA3035390C (fr) Gomme a macher en tablette avec administration amelioree de cannabin oides
CN113329743B (zh) 具有聚乙酸乙烯酯弹性体增塑剂的压片大麻素口香糖
CA3035381C (fr) Gomme a macher en tablette contenant des cannabinoides avec liberati on amelioree
CA3035400C (fr) Gomme a macher en tablette contenant des cannabinoides en couches
US20200276118A1 (en) Tableted cannabinoid chewing gum with improved release
US20240008514A1 (en) Cannabinoid Lipid Premixture
CA3166745A1 (fr) Premelange de lipides cannabinoides
WO2020177822A1 (fr) Gomme à mâcher en comprimés à administration améliorée de cannabinoïdes